Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
The INZY news page on Stock Titan provides an archive of public announcements, press releases, and transaction updates related to Inozyme Pharma, Inc., a former Nasdaq-listed clinical-stage biopharmaceutical company. According to company disclosures and SEC filings, Inozyme became a wholly owned subsidiary of BioMarin Pharmaceutical Inc. on July 1, 2025, and its common stock was subsequently delisted and deregistered. As a result, this page now functions as a historical news record for the INZY ticker.
Inozyme’s news flow has focused on the development of INZ-701, an ENPP1 Fc fusion protein enzyme replacement therapy, and on rare diseases linked to the PPi-Adenosine Pathway, including ENPP1 Deficiency and ABCC6 Deficiency. Press releases detail clinical trial progress in infants, children, and adults, interim data from pivotal and early-stage studies, expanded access program results, and natural history research published in peer-reviewed venues. Company updates also cover regulatory interactions in multiple regions, strategic prioritization of ENPP1 Deficiency programs, workforce adjustments, and participation in industry conferences.
For corporate and capital markets history, the news archive includes announcements of full-year and quarterly financial results, strategic reviews, and the sequence of events leading to the 2025 acquisition by BioMarin, including the signing of the merger agreement, tender offer details, postponement of the 2025 annual meeting of stockholders, and confirmation of transaction closing. Together with related SEC filings, these items document how Inozyme transitioned from an independent public issuer under the symbol INZY to a subsidiary within BioMarin.
Readers interested in the evolution of INZ-701, the characterization of ENPP1 and ABCC6 Deficiencies, and the corporate steps surrounding Inozyme’s acquisition can use this news page as a centralized reference. It brings together disease-focused scientific communications, clinical development milestones, and key transaction announcements associated with the historical INZY listing.
Inozyme Pharma (Nasdaq: INZY) announced the appointment of Yves Sabbagh, Ph.D., as the new senior vice president and chief scientific officer, marking a significant leadership change. Dr. Sabbagh brings over 20 years of experience in rare genetic disorders and mineral metabolism. He will focus on expanding Inozyme's proprietary pipeline. The company also confirmed the retirement of former CSO David Thompson, who will transition to a senior advisor role. Inozyme plans to enhance its R&D capabilities with new laboratory space in Boston.
Inozyme Pharma reported its Q2 2020 financial results, highlighting an upsized IPO that raised $128.8 million in July 2020. The company submitted its first IND for INZ-701 for treating ENPP1 deficiency, but the FDA placed the clinical trial on hold pending toxicity study reports. They expect trials to begin in early 2021. Cash reserves increased to $63.9 million by June 30, 2020, bolstered by IPO proceeds. R&D expenses rose to $7.9 million, reflecting intensified development activities. The net loss amounted to $9.5 million for the quarter.
Inozyme Pharma has successfully closed its initial public offering, selling 7,000,000 shares at $16.00 each, totaling $112 million, along with an additional 1,050,000 shares, bringing gross proceeds to $128.8 million. This offering marks a significant milestone as Inozyme's shares began trading on Nasdaq under the symbol 'INZY' on July 24, 2020. The underwriters for the offering included well-known firms such as BofA Securities and Cowen. Inozyme is focused on developing therapeutics for rare diseases linked to abnormal mineralization.